Shed Medical Leadership and Credentials: What Patients Need to Know

Who Runs Shed? Disclosed Medical Leadership

Shed does not prominently name a Chief Medical Officer or medical director on its public-facing website. That absence is notable. Established telehealth platforms in the GLP-1 space, such as Hims and Hers and Ro, publish the names, credentials, and state licensures of their clinical leadership teams.

What Shed's Website Does and Does Not Disclose

As of this review, Shed's site describes a clinical review process but stops short of identifying specific physicians by name. Patients are told a "licensed provider" will review their intake form. The platform does not list a named medical director, a supervising physician's DEA number, or a formal medical advisory board.

That matters for one simple reason: under state telehealth laws and prescribing regulations, a supervising or collaborating physician must be identifiable and accountable for the protocols governing mid-level prescribers. The Federation of State Medical Boards (FSMB) policy on interstate telehealth practice states that "a valid patient-physician relationship must be established" and that prescribing controlled or high-risk medications without that relationship "may constitute unprofessional conduct." [1]

Comparing Credential Transparency Across Platforms

Platforms like Found and Calibrate publish medical director names, board certifications (typically ABOM or AACE-affiliated), and links to state license verification tools. Shed does not offer this at the time of writing. Patients can use the NPPES National Provider Identifier registry at npiregistry.cms.hhs.gov to search for any clinician by name, but that search requires a name to begin with.

A useful three-question framework for evaluating any GLP-1 telehealth brand's credibility:

1. Can you find the medical director's name, NPI, and board certification before you pay?
2. Is the compounding pharmacy identified by name and verifiable as a 503B outsourcing facility or an accredited 503A pharmacy?
3. Does the platform disclose its clinical protocols, including how dose escalations are managed and what criteria trigger a referral to in-person care?

Shed currently answers none of these three questions on its public website.

Is Shed Legit? Evaluating Regulatory and Accreditation Status

"Legit" means different things in different contexts. A company can be legally incorporated, accept payments, and ship medications while still operating in a regulatory gray zone. The relevant questions are whether its prescribers hold valid licenses in the patient's state, whether its pharmacy partners comply with FDA compounding law, and whether the platform has earned third-party accreditation.

LegitScript Verification

LegitScript is the dominant third-party certification body for online pharmacies and telehealth prescribers in the United States. Its database, searchable at legitscript.com, categorizes online pharmacies as certified, not recommended, rogue, or monitor. A "not certified" status does not automatically mean illegal, but it means LegitScript has not independently verified the platform's prescribing and dispensing practices.

Shed does not appear in LegitScript's certified pharmacy or telehealth merchant list as of this review. Patients relying on their insurance or HSA/FSA accounts to pay for telehealth services should note that many payment processors and benefit administrators require LegitScript certification.

BBB Complaint Profile

The Better Business Bureau profile for Shed shows limited publicly accessible complaint data at the time of writing. That could reflect a young company with a small customer base, or it could reflect low complaint reporting rates. The BBB assigns accreditation based on transparency and responsiveness to complaints, not on clinical quality. Absence of BBB complaints does not validate medical safety.

FDA Compounding Enforcement Context

This is the most consequential regulatory issue for Shed and all compounded GLP-1 platforms. Semaglutide (Ozempic, Wegovy) was listed on the FDA drug shortage database, which created a legal pathway for 503A and 503B pharmacies to compound it under specific conditions. The FDA officially removed semaglutide from the shortage list in February 2025. [2]

Following that removal, the FDA issued guidance stating that 503B outsourcing facilities may no longer compound semaglutide for office stock, and that 503A pharmacies may only compound it with a valid patient-specific prescription and only when a "clinical difference" from the branded product can be documented. [3] The FDA has sent warning letters to multiple compounding operations and has stated it will pursue enforcement against platforms that continue bulk compounding without meeting these requirements. [4]

Shed, like all cash-pay compounded semaglutide platforms, must now document a patient-specific clinical rationale for each prescription or switch patients to branded drugs. Patients should ask Shed directly: which pharmacy fills your prescription, is it a 503A or 503B facility, and what is the documentation for your "clinical difference" claim?

Shed's Prescriber Model: Synchronous vs. Asynchronous Care

Telehealth prescribing for GLP-1 medications falls into two broad categories. Synchronous care involves a real-time video or phone visit with a licensed clinician. Asynchronous care involves the patient completing an intake questionnaire that a clinician reviews offline, often within 24 to 48 hours.

The Clinical Risks of Asynchronous-Only GLP-1 Prescribing

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that anti-obesity medications should be prescribed "as an adjunct to lifestyle intervention" and that patients require "ongoing follow-up to assess efficacy and safety." [5] An asynchronous intake form does not inherently provide that follow-up.

GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors in rodent studies, and they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. [6] They also carry clinically meaningful risks of pancreatitis, gallbladder disease, and severe gastrointestinal events. Identifying these contraindications depends on thorough history-taking. A checkbox questionnaire may not capture the nuance a synchronous interview would.

What to Expect from Shed's Clinical Process

Shed's intake process, based on publicly available descriptions, involves an online health questionnaire, a height and weight entry, and submission to a provider queue. The platform claims providers review submissions and send a prescription within one to two business days if approved. There is no clear indication that a video visit is required or offered.

Patients with complex medical histories, including a prior diagnosis of pancreatitis, personal history of eating disorders, current use of insulin or sulfonylureas, or cardiovascular disease, should speak directly with a physician before starting any GLP-1 program. A questionnaire reviewed asynchronously is not a substitute for that conversation.

Compounded Semaglutide: What the Evidence Actually Shows

Shed's primary product is compounded semaglutide. The clinical evidence base for the branded reference product is substantial, but that evidence does not automatically transfer to compounded versions.

Efficacy Data for Branded Semaglutide

In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body weight reduction of 14.9% at 68 weeks compared with 2.4% in the placebo group (P<0.001). [7] In STEP-4 (N=803), participants who continued semaglutide after a 20-week run-in maintained or further reduced their weight, while those who switched to placebo regained 6.9 percentage points of body weight by week 68. [8]

These results are for FDA-approved Wegovy (semaglutide 2.4 mg, Novo Nordisk), manufactured under GMP conditions, with validated pharmacokinetic profiles.

The Compounding Quality Gap

Compounded semaglutide is not FDA-approved. The FDA does not evaluate compounded drugs for safety, efficacy, or manufacturing quality before they reach patients. [3] The agency has identified compounded semaglutide products containing semaglutide sodium and semaglutide acetate, which are salt forms not used in the approved drug and which have no published clinical trial data supporting their safety or bioavailability. [4]

A 503B outsourcing facility operating under cGMP standards offers meaningfully stronger quality assurance than a small 503A pharmacy. Patients considering Shed should ask which type of facility fills their prescription and request a certificate of analysis for the specific batch.

Tirzepatide Compounding: An Even Narrower Window

Some reports indicate Shed has also offered compounded tirzepatide (the active ingredient in Mounjaro and Zepbound). Tirzepatide was removed from the FDA shortage list for most doses in early 2025 as well. [9] The same analysis applies: compounding exemptions tied to shortage status no longer apply, and the legal basis for continued compounding is narrow.

Shed Complaints: Patterns Worth Knowing

Consumer complaint platforms, including Trustpilot, Reddit (r/Semaglutide, r/WeightLossAdvice), and the BBB, contain recurring themes for many compounded GLP-1 services. Common complaint categories across the sector include delayed shipments, difficulty reaching customer support after payment, unexpected auto-renewal charges, and questions about whether the product received matched what was prescribed.

Specific Complaint Categories for Shed

Based on publicly available consumer reviews at the time of this writing, Shed complaints cluster around three areas. First, customers report that canceling a subscription is not straightforward, with some describing difficulty reaching a support representative by phone or live chat. Second, some users report receiving a lower dose than expected in their first shipment with limited explanation. Third, a subset of reviewers notes that the clinical interaction felt minimal, describing no follow-up contact after the initial prescription was issued.

None of these complaints constitute proof of fraud or illegal activity. They do reflect the broader challenge of asynchronous, subscription-based telehealth models where commercial incentives can outpace clinical oversight.

How to File a Complaint if You Have One

Patients with unresolved concerns have several options. A complaint about prescribing practice can be filed with the state medical board in the state where the prescribing clinician is licensed. A complaint about pharmacy dispensing can be filed with the state pharmacy board. A complaint about a compounded drug's quality or adverse effects can be submitted to FDA MedWatch at fda.gov/safety/medwatch. [10] Complaints about deceptive business practices can be filed with the FTC at ftc.gov.

What Legitimate GLP-1 Telehealth Oversight Looks Like

Understanding what strong oversight looks like helps patients evaluate platforms like Shed against a concrete standard.

Prescriber Accountability

Reputable GLP-1 telehealth programs name their medical director publicly, publish that person's NPI and board certification, and describe the clinical protocols governing prescribing decisions. The American Association of Clinical Endocrinology (AACE) 2023 obesity management guidelines call for individualized therapy with regular monitoring of weight, metabolic parameters, and adverse effects. [11] A credible platform translates those guidelines into a documented protocol.

Pharmacy Accountability

The United States Pharmacopeia (USP) sets compounding quality standards. A 503B outsourcing facility registered with the FDA and operating under cGMP provides a meaningfully higher assurance of product quality than a small 503A pharmacy. Patients can verify 503B registration at fda.gov/drugs/human-drug-compounding. [12]

Follow-Up and Dose Escalation

Wegovy's FDA-approved titration schedule increases the dose from 0.25 mg weekly to 2.4 mg weekly over 16 to 20 weeks to reduce gastrointestinal side effects. [6] A platform that ships a "standard dose" without a structured titration schedule and without clinician-monitored dose escalation is not following the evidence-based prescribing model.

The Obesity Medicine Association recommends that patients receiving GLP-1 therapy have at minimum a 4-week check-in after initiation, a 3-month metabolic reassessment, and a 6-month weight and adverse-event review. [13] Ask any telehealth platform, including Shed, whether these checkpoints are built into the program or whether the patient must initiate them.

Questions to Ask Shed Before You Pay

Patients deserve direct answers to direct questions. Below is a concrete list to present to Shed's customer or clinical support team before submitting payment.

• Who is the named medical director, and what state are they licensed in?
• Which pharmacy will fill my prescription, and is it a 503A or 503B facility?
• Can you provide a certificate of analysis for the compounded semaglutide batch?
• What is the documented clinical rationale for compounding rather than dispensing branded Wegovy?
• Is my initial consultation synchronous (live video or phone) or asynchronous?
• What is the dose titration schedule, and who monitors my dose escalations?
• How do I reach a clinician if I experience a side effect over a weekend?
• What is the cancellation policy, and is it in writing before I subscribe?

If the answers are vague, delayed, or unavailable, that is clinically meaningful information.